CCFA Conference Notes 2016 (part 3) -Malignancy and IBD

This blog entry has abbreviated/summarized this terrific presentation; most of the material has been covered in this blog in prior entries but still this was a useful review. Though not intentional, some important material is likely to have been omitted; in addition, transcription errors are possible as well.

3rd Lecture: Prevention and management of malignancy in IBD –Dr. Thomas Ullman

Malignancy risk (colorectal cancer [CRC]) is present with prolonged ulcerative colitis, though more recent studies have shown lower risk than in the past –not much higher than the general population.

Screen Shot 2016-04-17 at 12.02.04 PM

  • CRC surveillance–colonoscopy monitoring after 8-10 years. Typically colonoscopy every other year for most patients, every year in higher risk patients (eg. PSC).

Screen Shot 2016-04-17 at 12.01.37 PM

  • Unclear if chemoprevention is effective (5-ASA, thiopurines, others).
  • Chromoendoscopy “has not been consensus on its use in our field (yet).” It is time consuming and expensive and unclear if it will improve outcome.

Does medical therapy for IBD predispose to developing cancer?

  • Thiopurines increase the risk of malignancy. (Pasternak et al) though the risk returns to near baseline when stopped according to study below.

Screen Shot 2016-04-17 at 12.03.27 PM

  • No overall increased risk with anti-TNF agents with RCTs (may not follow patients long enough) but also not seen in Danish registry either (JAMA study)
With Anti-TNFs

No increased risk of malignancy in this study with Anti-TNFs

  • Lymphoma risks: age, immunodeficiency, EBV
  • EBV negative are at risk for HLH with thiopurines
  • HTSCL ~200, >90% men and >90% <35 years. NOT EBV-related. Has not been identified in anti-TNF monotherapy.

Screen Shot 2016-04-17 at 12.02.55 PM

  • Skin cancer –main concern is in non-melanoma skin cancer (possibly melanoma too). Skin cancer increase has not been noted with methotrexate. Prevention: Skin care, and annual dermatology visits.
  • Cervical cancer—likely increased risk in IBD, probably due to thiopurine exposure and reduced immune surveillance. Prevention: HPV vaccination, Pap testing.
  • Urinary Tract cancers –especially in those >65 years with thiopurine exposure


2 thoughts on “CCFA Conference Notes 2016 (part 3) -Malignancy and IBD

  1. Pingback: Safer Than You Think: Biologic Therapies for IBD and Risk of Infection and Malignancy | gutsandgrowth

  2. Pingback: Infliximab Not Associated with Malignancy | gutsandgrowth

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.